Phase II trial of exemestane in combination with fulvestrant in postmenopausal women with advanced, hormone-responsive breast cancer

Clinical Breast Cancer

Volumn 12, Issue 2, 2012, Pages 151-156

  Mrózek, Ewa ^a   Layman, Rachel ^a   Ramaswamy, Bhuvaneswari ^a   Schaaf, Larry ^a   Li, Xiaobai ^a   Ottman, Susan ^a   Shapiro, Charles L ^a  

^a OHIO STATE UNIVERSITY   (United States)

Author keywords

Endocrine therapy; Exemestane; Fulvestrant; IGF binding protein 3; Insulin like growth factor; Metastatic breast cancer

Indexed keywords

EXEMESTANE; FULVESTRANT; SOMATOMEDIN BINDING PROTEIN 3; SOMATOMEDIN C;

ADULT; ADVANCED CANCER; AGED; ANEMIA; ANOREXIA; ARTHRALGIA; ARTICLE; BLOOD TOXICITY; BONE PAIN; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; DRUG BLOOD LEVEL; DRUG EFFICACY; DYSPNEA; FATIGUE; FEMALE; HUMAN; HYPERCALCEMIA; MONOTHERAPY; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUTROPENIA; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE; PROGRESSION FREE SURVIVAL; THORAX PAIN; THROMBOCYTOPENIA; THROMBOEMBOLISM; TREATMENT RESPONSE; VOMITING;

EID: 84858954261     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2012.01.003     Document Type: Article

References (33)

1. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005; 365:1687-717.
2. The Arimidex, Tamoxifen, Alone or in Combination (ATAC) Trialists' Group, Forbes JF, Cuzick J, et al. Effect of anastrazole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9:45-53.
3. Thürlimann B, Keshaviah A, Coates AS, et al. A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353:2747-57. (Pubitemid 43016814)
4. Coombes RC, Kilburn LS, Snowdon CF, et al. Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (intergroup exemestane study): a randomized controlled trial. Lancet 2007; 369:559-70.
5. Goss PE, Ingle JN, Martino S, et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA. J Natl Cancer Inst 2005; 97:1262-71. (Pubitemid 41535367)
6. Goss PE, Ingle JN, Chapman J-AW, et al. Final analysis of NCIC CTG MA. 27: a randomized phase III trial of exemestane versus anastrozole in postmenopausal women with hormone receptor positive breast cancer. Cancer Res 2010; 70(suppl 2):75s (abstract S1-1).
7. Gibson L, Lawrence D, Dawson C, et al. Aromatase inhibitors for treatment of advanced breast cancer in postmenopausal women. Cochrane Database Syst Rev 2009; (4):CD003370.
8. Hayes DF, Van Zyl JA, Hacking A, et al. Randomized comparison of tamoxifen and two separate doses of toremifene in postmenopausal patients with metastatic breast cancer. J Clin Oncol 1995; 13:2556-66.
9. Buzdar A, Douma J, Davidson N, et al. Phase II, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001; 19:3357-66. (Pubitemid 32642188)
10. Nabholtz JM, Buzdar A, Pollack M, et al. Anastrazole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000; 18:3758-67.
11. Paridaens RJ, Therasse P, Dirix LV, et al. Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organization for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008; 26:4883-90.
12. Robertson JF, Osborne CK, Howell A, et al. Fulvestrant versus anastrazole for the treatment of advanced breast carcinoma in postmenopausal women: a prospective combined analysis of two multicenter trials. Cancer 2003; 98:229-38. (Pubitemid 36828445)
13. Ellis MJ, Gao F, Dehdashti F, et al. Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009; 302:774-80.
14. Dowsett M, Martin LA, Smith I, et al. Mechanisms of resistance to aromatase inhibitors. J Steroid Biochem Mol Biol 2005; 95:167-72. (Pubitemid 41137307)
15. Bedard PL, Freedman OC, Howell A, et al. Overcoming endocrine resistance in breast cancer: are signal transduction inhibitors the answer? Breast Cancer Res Treat 2008; 108:307-17. (Pubitemid 351431070)
16. Johnson SRD, Martin L-A, Head J, et al. Aromatase inhibitors: combinations with fulvestrant or signal transduction inhibitors as a strategy to overcome endocrine resistance. J Steroid Biochem Mol Biol 2005; 95:173-81. (Pubitemid 41137308)
17. Osipo C, Gajdos C, Liu H, et al. Paradoxical action of fulvestrant in estradiol-induced regression of tamoxifen-stimulated breast cancer. J Natl Cancer Inst 2003; 95:1597-608. (Pubitemid 37455927)
18. Macedo LF, Sabnis GJ, Goloubeva OG, et al. Combination of anastrazole with fulvestrant in the intratumoral aromatase xenograft model. Cancer Res 2008; 68:3516-22.
19. Lien EA, Johannessen DC, Aakvaag A, et al. Influence of tamoxifen, aminoglutethimide and goserelin on human plasma IGF-I levels in breast cancer patients. J Steroid Biochem Mol Biol 1992; 41:541-3.
20. Ferrari L, Bajetta E, Martinetti A, et al. Could exemestane affect insulin-like growth factors, interleukin 6 and bone metabolism in postmenopausal advanced breast cancer patients after failure on aminoglutethimide, anastrazole or letrozole? Int J Oncol 2003; 22:1081-9.
21. Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45:228-47.
22. Chia S, Gradishar W, Mauriac L, et al. Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008; 26:1664-70.
23. Lønning PE, Bajetta E, Murray R, et al. Activity of exemestane in metastatic breast cancer after failure of nonsteroidal aromatase inhibitors: a phase II trial. J Clin Oncol 2000; 18:2234-44. (Pubitemid 30350215)
24. Howell A, Robertson JFR, Abram P, et al. Comparison of fulvestrant versus tamoxifen for the treatment of advanced breast cancer in postmenopausal women previously untreated with endocrine therapy: a multinational, double-blind randomized trial. J Clin Oncol 2004; 22:1605-13. (Pubitemid 41079798)
25. Osborne CK, Pippen J, Jones SE, et al. Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrazole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy; results of a North American trial. J Clin Oncol 2002; 20:3386-95.
26. Robertson JFR. Fulvestrant (Faslodex)-how to make a good drug better. Oncologist 2007; 12:774-84. (Pubitemid 47328221)
27. Buzdar AU, Robertson JFR, Eiermann W, et al. An overview of the pharmacology and pharmacokinetics of the newer generation aromatase inhibitors anastrazole, letrozole and exemestane. Cancer 2002; 95:2006-16. (Pubitemid 35222182)
28. Howell A, Bergh J. Insights into the place of fulvestrant for the treatment of advanced endocrine responsive breast cancer. J Clin Oncol 2010; 28:4548-50.
29. Ohno S, Rai Y, Iwata H, et al. Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol 2010; 21:2342-7.
30. Pritchard KI, Rolski J, Papai Z, et al. Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat 2010; 123:453-61.
31. Baum M, Buzdar A, Cuzick J, et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early-stage breast cancer: results of the ATAC (Arimidex, tamoxifen alone or in combination) trial efficacy and safety update analyses. Cancer 2003; 98:1802-10. (Pubitemid 37310221)
32. Zhang Y, Moerkens M, Ramaiaghari S, et al. Elevated insulin-like growth factor 1 receptor signaling induces antiestrogen resistance through the MAPK/ERK and PI3K/Akt signaling routes. Breast Cancer Res 2011; 13:R52.
33. Ibrahim YH, Yee D. Insulin-like growth factor-1 and breast cancer therapy. Clin Cancer Res 2005; 11:944-50.